Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs

Breccia, Massimo; Alimena, Giuliana
January 2014
Mediterranean Journal of Hematology & Infectious Diseases;2014, Vol. 6 Issue 1, p1
Academic Journal
With the advent of target therapies, imatinib became the mainstay for treatment of chronic myeloid leukemia. However, despite the brilliant results obtained with this drug, more than 30% of patients discontinue therapy in long-term due to several reasons, including failure and/or intolerance. Second-generation tyrosine kinase inhibitors (TKIs) are more potent drugs and have expanded inhibition against a broad spectrum of mutations resistant to imatinib. Both nilotinib and dasatinib have demonstrated in vitro and in vivo clinical activity against different types of mutations and various forms of resistance. However, patients with T315I mutation do not obtain an advantage from these drugs and a third generation inhibitor ponatinib, a pan-BCR drug, was tested with significant results. In this review, we report the results of second- and third-generation TKIs tested as second or third line therapy in patients resistant and/or intolerant to previous inhibitors.


Related Articles

  • Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Gounder, Mrinal; Maki, Robert // Cancer Chemotherapy & Pharmacology;Jan2011 Supplement, Vol. 67 Issue 1, p25 

    Small molecule kinase inhibitors have irrevocably altered cancer treatment. March 2010 marks the 10th anniversary of using imatinib in gastrointestinal stromal tumors (GIST), a cardinal example of the utility of such targeted therapy in a solid tumor. Before imatinib, metastatic GIST was...

  • A Critical History of Chromic Myeloid Leukemia. Baccarani, Michele; Pane, Fabrizio // Mediterranean Journal of Hematology & Infectious Diseases;2014, Vol. 6 Issue 1, p1 

    The author reflects on various developments in treatment of chronic myeloid leukemia (CML), a cancer of white blood cells (WBCs). Topics discussed include development of targeted treatments for CML such as by targeting the tyrosine kinase inhibitors (TKIs), history of treatment of CML such as by...

  • Systematic review of dasatinib in chronic myeloid leukemia. Breccia, Massimo; Salaroli, Adriano; Molica, Matteo; Alimena, Giuliana // OncoTargets & Therapy;2013, Vol. 6, p257 

    Dasatinib is a dual tyrosine kinase inhibitor active against ABL and Src family kinases, and is approved for the treatment of chronic myeloid leukemia (CML) patients in chronic, accelerated, or blast phase with resistance or intolerance to imatinib therapy, for newly diagnosed chronic phase...

  • BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. Liu, J.; Joha, S.; Idziorek, T.; Corm, S.; Hetuin, D.; Philippe, N.; Preudhomme, C.; Quesnel, B. // Leukemia (08876924);Apr2008, Vol. 22 Issue 4, p791 

    Patients with chronic myeloid leukemia who become resistant to the Abl kinase inhibitor imatinib can be treated with dasatinib. This sequential treatment can lead to BCR-ABL mutations conferring broad resistance to kinase inhibitors. To model the evolution of resistance, we exposed the mouse...

  • Nilotinib-Associated Destructive Thyroiditis. Bakerywala, Suhalia; Schwarcz, Monica D.; Goldberg, Michael D.; Valiquette, Guy; Weiss, Irene A. // Case Reports in Endocrinology;5/7/2015, Vol. 2015, p1 

    Protein tyrosine kinase inhibitors are currently an important drug class in the treatment of leukemia. They represent targeted cancer therapy and have become the treatment of choice in chronic myeloid leukemia. Tyrosine kinases are enzymes expressed in multiple tissues and are involved in...

  • Tyrosine Kinase Inhibitors and Interferon. Dimou, Maria; Panayiotidis, Panagiotis // Mediterranean Journal of Hematology & Infectious Diseases;2014, Vol. 6 Issue 1, p1 

    The use of interferon-a (INF) in chronic myeloid leukemia, when it started in the 80s, was considered as a breakthrough in the therapy of this disease; INF administered alone or in combination with aracytin was the standard choice for treatment for Chronic Myeloid Leukemia (CML) patients unfit...

  • Key Decision Just After 3 Months Following TKI Initiation in CML: Better and not Difficult. HAZNEDAROGLU, Ibrahim C. // International Journal of Hematology & Oncology / UHOD: Uluslarar;2013 Supplement, Vol. 23 Issue 1, p1 

    A letter to the editor is presented regarding the use of tyrosine kinase inhibitor (TKI) in the management of chronic myeloid leukemia (CML) is presented.

  • Indolinone Derivatives Inhibit Constitutively Activated KIT Mutants and Kill Neoplastic Mast Cells. Ma, Yongsheng; Carter, Eric; Wang, Xiaomei; Shu, Chang; McMahon, Gerald; Longley, B. Jack // Journal of Investigative Dermatology;Feb2000, Vol. 114 Issue 2, p392 

    Summary Mastocytosis is a neoplastic disease caused at least in part by somatic mutations of the c-KIT proto-oncogene resulting in constitutive activation of its protein product, KIT, the receptor tyrosine kinase for stem cell factor. KIT stimulates mast cell proliferation and prevents apoptosis...

  • Sorafenib.  // Reactions Weekly;10/13/2012, Issue 1423, p45 

    The article describes the case of a male patient who developed occlusive coronary artery disease while undergoing sorafenib therapy for metastatic renal cell carcinoma.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics